Johnson & Johnson reveals obesity and 3D printing collaborations
Johnson & Johnson (J&J) Innovation, the division that focuses on forming collaborations between entrepreneurs and J&J’s healthcare businesses, has announced a series of new collaborations.
Janssen Pharmaceuticals, a subsidiary of J&J, has formed a multi-project collaboration with the University of California San Diego School of Medicine.
The collaboration will identify pathways and mechanisms driving disease progression, as well as clinically useful biomarkers, therapeutic targets and gastric bypass approaches that could yield improved treatments for obesity and related conditions.
Johnson & Johnson Services, another division of J&J, has executed a research collaboration with Inkbit Corporation, a 3D printing startup recently spun out of the Massachusetts Institute of Technology.
“3D printing holds the potential to create customised health solutions that can mean increased satisfaction and better outcomes for patients,” said J&J Innovation in a statement released yesterday, June 15.
Janssen Biotech has formed a multi-year collaboration and prenegotiated option-to-license agreement with Monash University, Australia, to discover and develop biologic next-generation therapeutics to treat, prevent and intercept rheumatoid arthritis.
According to J&J, rheumatoid arthritis affects more than 1.3 million adults in the US and nearly 1% of the world’s population.
Other partnerships will focus on advancing improvements for contact lenses, improving manufacturing efficiencies, and developing a platform that learns how human microbiome communities interact with the host through analysis of genetic, functional and metabolic data.
Additionally, through an effort to advance global public health, Janssen Pharmaceutical Companies is sharing its molecular compound libraries with collaborators developing treatments for diseases of the developing world.
Paul Stoffels, chief scientific officer of J&J, said: "Fulfilling the unmet needs facing patients today requires continued investment in the ideas that could become the healthcare solutions that improve and extend patients’ lives in the future.”
Today’s stories:
Section 101 raises fundamental question: 3M
Panellists tackle patent concerns after Brexit
FBI agent and lawyers provide trade secret tips
Industry at a crossroads over section 101
Pfizer and Takeda help to tackle Africa cancer crisis
Academic patents gave $1.3tn to US output
David Cameron talks Brexit, Trump and genomes
Hospira sued for infringing allergic injection patent
Google’s parent company invests $300m in biotech
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.